



Aims and Objectives:

To undertake a large-scale genomic study to identify the genes, and biological pathways they control, which **determine susceptibility and severity in life-threatening bacterial infections of childhood** in Europe and globally.

To develop an integrated staged approach using meningococcal disease as the prototypic model.

To apply the approach to the other major bacterial infections of childhood.

Funding:

This is a FP7 collaborative project funded by the European Commission: GA 279182

Partners:

Imperial College London; University of Liverpool; University of Oxford; Academisch Medisch Centrum Bij de Universiteit van Amsterdam; Erasmus Universitair Medisch Centrum; Radboud University Nijmegen Medical Centre; Medizinische Universitaet Graz; Servicio Galego de Saude and Fundación IDICHUS; Genome Institute of Singapore; Oxford Gene Technology; Micropathology Ltd; MRC - The Gambia Unit; Novartis Vaccines and Diagnostics; Imperial Consultants



www.euclids-project.eu

Workshop: State-of-the-art approaches for clinical studies of bacterial infectious diseases

26th October 2012

AC Palacio del Carmen Hotel, Santiago de Compostela, Spain

Preliminary programme:

Applied genomics for bacterial infectious diseases.

What transcriptomics can tell us about childhood respiratory infection?

Computational and statistical approaches to find DNA and RNA biomarkers.

Molecular Genetics: from the lab to the bedside.

Tomorrow's role of clinical doctors in the study of bacterial infectious diseases.

Functional Genetics: exploring genetic associations.

Networking dinner.

Confirmed speakers:

F. Martín-Torres

M. Levin

L. Coin

H. Eleftherohorinou

J. Herberg

D. Serruto

M. van der Flier

M. C. Brouwer

K. Bojang

Online registration:

www.euclids-project.eu/2012

Attendance fee €40; Dinner €50

Deadline: August 31st 2012

Coordinators:

F. Martín-Torres - Hospital Clínico Universitario De Santiago

M. Levin - Imperial College London
EUCLIDS network



Travel grants are available for Spanish attendees courtesy of Sanofi Pasteur MSD, Pfizer and Novartis Vaccines Spain

